RCT: Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma.

Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)

Commentary: Elotuzumab Does Not Improve PFS in Newly Diagnosed Multiple Myeloma – Cancer Therapy Adviser

Commentary on Twitter

NEW research— Addition of elotuzumab to lenalidomide and dexamethasone did not improve progression-free survival in patients w/ newly diagnosed, transplantation ineligible multiple myeloma: results of the ph3 ELOQUENT-1 trial #mmsm https://t.co/8O3O6ikCJO pic.twitter.com/qe5V7Om9DN

— The Lancet Haematology (@TheLancetHaem) May 12, 2022